HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis early-stage study tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer and tumors with a specific gene change (CCNE1). The main goals are to find a safe dose and see how well the drug works. About 361 participants will…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug QL1706 to standard chemotherapy can eliminate more cancer before surgery in people with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then have surgery. After surgery…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New hope for advanced breast cancer: drug combo trial launches
Disease control Recruiting nowThis study tests two experimental drugs, sapanisertib and serabelisib, combined with other therapies for people with HR+/HER2- advanced or metastatic breast cancer. The goal is to find safe doses and see if the combinations shrink tumors. About 32 participants will join this earl…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New pill AVZO-023 takes on advanced cancers in first human trial
Disease control Recruiting nowThis study is the first to test AVZO-023, an oral drug that blocks a protein called CDK4, in people with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if it can shrink tumors. About 380 adults with HR+/HER2- brea…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New drug elacestrant aims to keep High-Risk breast cancer at bay
Disease control Recruiting nowThis study tests if a new hormone therapy called elacestrant, taken for 5 years, can better prevent breast cancer from coming back compared to standard hormone therapy in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New hope for early breast cancer: drug combo aims to stop recurrence
Disease control Recruiting nowThis study is testing whether adding the drug dalpiciclib to standard hormone therapy can help keep early-stage HR+/HER2- breast cancer from returning. About 2000 women with stage II or III breast cancer will receive either a lower dose for 3 years or a higher dose for 2 years. T…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Real-World data sought on powerful breast cancer drugs
Knowledge-focused Recruiting nowThis study is tracking 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these drugs control the cancer in real-world settings. The goal is to gather information …
Matched conditions: HR+/HER2- BREAST CANCER
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 26, 2026 03:12 UTC